My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
2024_OpioidSettlemtAgrmt_JanssenJJ
>
Meetings
>
2024
>
04. April
>
2024-04-16 10:00 AM - Commissioners' Agenda
>
2024_OpioidSettlemtAgrmt_JanssenJJ
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
4/11/2024 1:10:33 PM
Creation date
4/11/2024 1:08:48 PM
Metadata
Fields
Template:
Meeting
Date
4/16/2024
Meeting title
Commissioners' Agenda
Location
Commissioners' Auditorium
Address
205 West 5th Room 109 - Ellensburg
Meeting type
Regular
Meeting document type
Supporting documentation
Supplemental fields
Item
Request to Approve a Resolution Accepting the Johnson & Johnson (Janssen) Washington State State-Wide Opioid Settlement Agreement
Order
7
Placement
Consent Agenda
Row ID
116716
Type
Agreement
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
127
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
<br />J-12 <br /> <br /> <br />10. Create or support community-based education or intervention services for families, <br />youth, and adolescents at risk for OUD and any co-occurring SUD/MH conditions. <br />11. Support evidence-informed programs or curricula to address mental health needs of <br />young people who may be at risk of misusing opioids or other drugs, including <br />emotional modulation and resilience skills. <br />12. Support greater access to mental health services and supports for young people, <br />including services and supports provided by school nurses, behavioral health workers <br />or other school staff, to address mental health needs in young people that (when not <br />properly addressed) increase the risk of opioid or another drug misuse. <br />H. PREVENT OVERDOSE DEATHS AND OTHER HARMS (HARM REDUCTION) <br />Support efforts to prevent or reduce overdose deaths or other opioid-related harms <br />through evidence-based or evidence-informed programs or strategies that may include, <br />but are not limited to, the following: <br />1. Increased availability and distribution of naloxone and other drugs that treat <br />overdoses for first responders, overdose patients, individuals with OUD and their <br />friends and family members, schools, community navigators and outreach workers, <br />persons being released from jail or prison, or other members of the general public. <br />2. Public health entities providing free naloxone to anyone in the community. <br />3. Training and education regarding naloxone and other drugs that treat overdoses for <br />first responders, overdose patients, patients taking opioids, families, schools, <br />community support groups, and other members of the general public. <br />4. Enabling school nurses and other school staff to respond to opioid overdoses, and <br />provide them with naloxone, training, and support. <br />5. Expanding, improving, or developing data tracking software and applications for <br />overdoses/naloxone revivals. <br />6. Public education relating to emergency responses to overdoses. <br />7. Public education relating to immunity and Good Samaritan laws. <br />8. Educating first responders regarding the existence and operation of immunity and <br />Good Samaritan laws. <br />9. Syringe service programs and other evidence-informed programs to reduce harms <br />associated with intravenous drug use, including supplies, staffing, space, peer support <br />services, referrals to treatment, fentanyl checking, connections to care, and the full <br />range of harm reduction and treatment services provided by these programs.
The URL can be used to link to this page
Your browser does not support the video tag.